Dr Reddy’s Labs Q3 FY25 profit up 2% YoY at Rs. 1,413 Cr
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Mothers Against Vaping also highlights a recent study of young people at risk of experiencing significant respiratory symptoms after just 30 days of electronic cigarette and other new age gateway products use
Tobacco smoke increases infant morbidity and is fatal to a baby because it damages the baby’s organs
The hospital is committed to adding to specialised practices in the healthcare space with its pioneering effort to promote oral health awareness and tobacco addiction prevention
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
At present 18 per cent of the local pharmaceutical market is under government's price control
Innovative solutions and a deep understanding of the market makes this a unique combination
Subscribe To Our Newsletter & Stay Updated